Pitfalls and Promise of Central Nervous System Drug Discovery
Central Nervous System disorders, and particularly neurodegenerative disorders, impact large proportions of the population and are among the most difficult targets for drug discovery. Furthermore, some of the problem is a result of science driven by the business interests, rather than the opposite. However, a careful evaluation of the reasons for past failures can provide insights into ways to improve future approaches. Join Valentin Gribkoff of TheraStat LLC and Yale University School of Medicine in this interactive free broadcast as he discusses the degree and nature of the problem and its effects on the willingness of the pharmaceutical industry to invest in the exploration of novel CNS therapies. During this webinar, you will discover possible solutions to some of the industry’s reluctance to enter or continue in pursuit of these targets.
What You Will Learn
- What are the recent CNS findings and work in progress, as well as what will make some of these targets more amenable
- What are the major remaining targets for novel CNS therapeutics and why have they been so difficult thus far
- Why multi-drug approaches (drug ‘cocktails’) may be difficult in terms of regulatory issues, and may be difficult to manage from a clinical trial perspective, but may be required for successful interventions
Benefits of Membership
- ACS Webinars Archive: Every one of our 200+ past webinars available on demand
- Save Money: Members receive discounts on meetings, development courses and more!
- Access to SciFinder®: Members receive 25 complimentary SciFinder® research activities per year
The Fine Print
ACS Webinars® does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.